Patrapim Sunpaweravong MD*, Supaporn Suwiwat PhD**, Somkiat Sunpaweravong MD***, Puttisak Puttawibul MD***, Winyou Mitarnun MD**
Affiliation : * Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand ** Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand *** Department of Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Background : The epidermal growth factor receptor (EGFR) has become a promising target for novel anticancer
therapy. Evaluation of its biological profiles including gene mutation, amplification, and protein expression
in  esophageal  squamous  cell  carcinoma  (ESCC)  is  essential  to  establish  the  EGFR  molecular  feature(s)
suitable to select patients in anti-EGFR therapy.
Material  and  Method:  The  subjects’  specimens  of  ESCC  at  Songklanagarind  Hospital  were  obtained  and
investigated  for  EGFR  protein  expression  and  gene  amplification.  Polymerase  chain  reaction  (PCR)  was
performed to amplify the EGFR DNA product. The mutational status of EGFR exons 19 and 21 was analyzed
using direct sequencing. The entire biological profiles of the EGFR were then correlated.
Results : There were 48 eligible ESCC specimens. No somatic mutation in the tyrosine kinase domain of EGFR
was detected. A high level of EGFR protein was exhibited in 22 patients (46%). Twenty-three patients (48%)
had shown a high gene copy numbers. However, no direct correlation between EGFR protein and gene status
was observed.
Conclusion : EGFR mutations in the tyrosine kinase domain of exons 19 and 21 were absent in ESCC, whereas,
protein  overexpression  and  gene  amplification  was  prevalent.  Therefore,  selection  of  ESCC  patients  for
studies  with  anti-EGFR  agents  based  on  protein  expression  or  gene  copy  number,  not  gene  mutation,  is
rational.
Keywords : Epidermal growth factor receptor, Mutation, Immunohistochemistry, Fluorescence in situ hybridization, Esophageal, Squamous cell carcinoma
                JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
4th Floor, Royal Golden Jubilee Building,
2 Soi Soonvijai, New Petchburi road,
Bangkok 10310, Thailand.
Phone: 0-2716-6102, 0-2716-6962
Fax: 0-2314-6305
Email: editor@jmatonline.com
  
                    » Online Submissions » Author Guidelines » Copyright Notice » Privacy Statement
» Journal Sponsorship » Site Map » About this Publishing System
© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.